Transfusion-Associated Graft-Versus-Host Disease

Transfusion-Associated Graft-Versus-Host Disease255platelet components. Semin Hematol 2001;4( Suppl 11):34-45.40. FunkhouserAW,VogelsangG,ZehnbauerB,Tunnessen WW, Beschorner WE, Sanders M, Graeber JE,Goodnough LT, Johnston MF, Ramsey G, Sayers MH,Eisenstadt RS, Anderson KC, Rutman RC, SilbersteinLE. Guidelines for transfusion support in patientsundergoing coronary artery bypass grafting. Transfusion Practices Committee of the American Association of Blood Banks. Annals of Thoracic Surgery 1990;50: 675-83.41. Asai T, Inaba S, Ohto H, Osada K, Suzuki G, TakahashiK, Tadokoro K, Minami M. Guidelines for irradiationof blood and blood components to prevent posttransfusiongraft-vs-host disease in Japan.TransfusionMedicine 2000;10:312-20.42. Moroff G, Holme S, AuBuchon JP, Heaton WA,Sweeney JD, Friedman LI. Viability and in vitroproperties of AS-1 red cells after gamma irradiation.Transfusion 1999;39:128-34.43. Lowenthal RM, Challis DR, Griffiths AE, et al. Transfusiono-associated graft-versus-host disease: report ofan occurrence following the administration of irradiatedblood. Transfusion 1993;33:524-9.44. Menitove JE. Standards for Blood Banks and TransfusionServices,19theds. Bethesda,MD. AmAssocBlood Banks, 1999.45. BCSH Blood Transfusion Task Force Guidelines ongamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease.Transfusion Medicine 1996;6:261-71.46. Akahoshi M, Takanashi M, Masuda M, Yamashita H,Hidano A, Hasegawa K, Kasajima T, Shimizu M, MotojiT, Oshimi K, Mizoguchi H. A case of transfusionassociatedgraftversus-hostdiseasenotpreventedbywhite cell-reduction filters. Transfusion 1992;32:169-72.47. Council of Europe Expert Committee in Blood Transfusion Study Group on Pathogen Inactivation of LabileBlood Components. Pathogen inactivation of labileblood products. Transfusion Medicine 2001;11:149-75.วารสารโลหิตวิทยาและเวชศาสตรบริการโลหิต ปที่ 12 ฉบับที่ 3 กรกฎาคม-กันยายน 2545